Thermo Fisher Scientific TMO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Consolidated revenues by Business | ||||||
| Analytical Instruments | $1.72B-0.1% | $2.22B+1.3% | $1.89B+4.7% | $1.73B-3.0% | $1.72B+1.8% | |
| Laboratory Products and Biopharma Services | $6.04B+7.0% | $6.38B+7.5% | $5.97B+4.0% | $6B— | $5.64B— | |
| Life Sciences Solutions | $2.64B+12.6% | $2.95B+13.1% | $2.59B+8.4% | $2.5B+6.1% | $2.34B+2.5% | |
| Specialty Diagnostics | $1.14B-0.5% | $1.22B+5.4% | $1.17B+4.0% | $1.13B+1.5% | $1.15B+3.5% | |
| Consolidated revenues by Product | ||||||
| Consumables | $4.72B+8.5% | $5.03B+11.3% | $4.68B+6.9% | $4.61B+5.5% | $4.35B+0.6% | |
| Instruments | $1.56B-4.4% | $2.22B-1.3% | $1.81B+2.4% | $1.64B-8.7% | $1.63B-0.1% | |
| Service revenues | $4.73B+7.8% | $4.97B+7.4% | $4.63B+4.1% | $4.61B+5.2% | $4.38B-0.1% | |
| Consolidated revenues by Geography | ||||||
| Asia-Pacific | $1.97B+4.2% | $2.28B+3.5% | $2.01B+4.7% | $1.92B-2.6% | $1.89B+1.6% | |
| Europe | $2.96B+12.7% | $3.37B+16.5% | $3.01B+11.9% | $2.83B+6.3% | $2.62B+0.2% | |
| North America | $5.71B+3.5% | $6.11B+4.2% | $5.69B+1.8% | $5.72B+3.5% | $5.51B-0.1% | |
| Other regions | $372M+10.4% | $462M+5.2% | $415M+4.5% | $383M+1.1% | $337M-2.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Thermo Fisher Scientific break its business down?
- Thermo Fisher Scientific (TMO) reports consolidated revenues by business across 4 parts — Analytical Instruments, Laboratory Products and Biopharma Services, Life Sciences Solutions and Specialty Diagnostics. Each is extracted from the segment footnotes and tracked over time.
- Where does Thermo Fisher Scientific's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Thermo Fisher Scientific's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
